Insys Therapeutics

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Retrieved on: 
Lunedì, Maggio 20, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, Bristol Myers Squibb, Patient, Neuroscience, Abivax, Ferris State University, Depression, Esperies, Therapy, Sale, Insys Therapeutics, Idiopathic pulmonary fibrosis, Audit committee, IPO, Esperion Therapeutics, DSM-IV codes, Juventas, Inflammation, Eli Lilly, AstraZeneca, Pharmaceutical industry

Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum’s board.

Key Points: 
  • Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum’s board.
  • “I am extremely pleased to welcome Troy to the Contineum board.
  • Currently, Mr. Ignelzi serves as the Chief Financial Officer at Rapport Therapeutics, Inc., a precision neuromedicines company, where he has served since November 2023.
  • “I am excited to bring my experience with neuroscience companies to the Contineum board and help guide the company’s financial strategy and growth.”

Province, the Nationally Recognized Restructuring and Financial Advisory Firm, Appoints Healthcare Veteran Kaile Zagger as Managing Director and Chair of Its Healthcare Practice Group

Retrieved on: 
Mercoledì, Maggio 8, 2024
Legal, Insurance, Finance, Consulting, Banking, Accounting, Professional Services, Other Health, Health, Organization, American College, Femtech, Fortune 500, Purdue Pharma, Patient, Trust, Multimedia, Insys Therapeutics, Therapy, Biotechnology, Pharmaceutical industry

Province takes special pride in announcing the appointment of renowned healthcare executive Kaile Zagger, to lead their nationally recognized innovative healthcare practice group.

Key Points: 
  • Province takes special pride in announcing the appointment of renowned healthcare executive Kaile Zagger, to lead their nationally recognized innovative healthcare practice group.
  • Ms. Zagger brings more than two decades of executive leadership healthcare experience in publicly traded and privately held healthcare organizations.
  • Province was retained in a leading role in various healthcare cases such as Purdue Pharma, Insys Therapeutics, Mallinckrodt, Codiak, and Mariner Healthcare.
  • Province has provided these and other clients with successful corporate and financial advisory as well as litigation services.

Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor

Retrieved on: 
Martedì, Marzo 12, 2024
Professional Services, Health, Other Science, Finance, Research, Science, Biotechnology, RAPS, Eli Lilly, AstraZeneca, Ferris State University, Patient, Esperion Therapeutics, Sale, IPO, Pleasure, Esperies, Insys Therapeutics, Therapy, Investment, Multimedia, Pharmaceutical industry

Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.

Key Points: 
  • Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240312683597/en/
    Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors.
  • Over the course of his career, Mr. Ignelzi has raised an impressive $4 billion-plus in capital for life science companies.
  • We are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments.

Rapport Therapeutics Appoints Chief Financial Officer

Retrieved on: 
Lunedì, Ottobre 30, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Science, IPO, Sale, AstraZeneca, Abivax, RAPS, Esperion Therapeutics, Eli Lilly, Esperies, Insys Therapeutics, Multimedia, DSM-IV codes, Ferris State University, Therapy, Patient, Pharmaceutical industry, Rapport

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231030359557/en/
    “We are thrilled to welcome Troy to the Rapport executive team during this time of rapid progress for our company,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • Most recently, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings.
  • Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals.

Fentanyl False Claims Act Qui Tam Case Leads to $9M Settlement

Retrieved on: 
Giovedì, Giugno 1, 2023
Controlled Substances Act, Centers for Medicare & Medicaid Services, CMS, Haggerty, TRICARE, Prescription, False Claims Act, Pharmacy, Ground substance, Complaint, Cancer pain, Patient, Associate, FCA, Federation, Purdue University, FDA, Therapy, Death, Pharmaceutical industry, Medicaid, Insys Therapeutics, Medicare

PHILADELPHIA, June 1, 2023 /PRNewswire/ -- Kang Haggerty LLC announced today that they obtained a $9 Million settlement in a non-intervened fentanyl false claims act qui tam case against private equity firm Belhealth Investment Partners, its principals, Harold Blue, Inder Tallur, and Dennis Drislane, and its pharmacy portfolio companies, Linden Care and Quick Care.

Key Points: 
  • PHILADELPHIA, June 1, 2023 /PRNewswire/ -- Kang Haggerty LLC announced today that they obtained a $9 Million settlement in a non-intervened fentanyl false claims act qui tam case against private equity firm Belhealth Investment Partners, its principals, Harold Blue, Inder Tallur, and Dennis Drislane, and its pharmacy portfolio companies, Linden Care and Quick Care.
  • The parties have agreed to settle alleged violations of the False Claims Act (FCA) based on a complaint originally filed in 2016, asserting that the settling defendants violated the False Claims Act, §§ 3729-3722, and related laws, by conspiring to submit, submitting, and/or causing the submission of false claims for payment to the federal and state governments for prescriptions of Subsys, a potent, rapid-onset fentanyl sublingual spray.
  • The federal government and seven state governments intervened in this case (and four other FCA cases) in 2018 only as to the claims against Defendant Insys Therapeutics, Inc., the well-known defunct manufacturer of Subsys.
  • Approximately $1.7 billion (or 30%) of the amount recovered in 2021 was a result of qui tam filings.

REID COLLINS & TSAI LLP RECOVERS $175 MILLION SETTLEMENT FROM FORMER INSYS DIRECTORS IN OPIOID-RELATED LAWSUIT

Retrieved on: 
Venerdì, Aprile 14, 2023
Lawsuit, Insurance, D&O, Marketing, HBO, NBC News, Front line, Trust, Insys Therapeutics, Madden, Judgement, Axa XL, Del, Federation, FDA, Therapy, News, Bankruptcy, Pharmaceutical industry, Caremark, Insys

National trial firm Reid Collins & Tsai LLP represents Insys Liquidation Trust in lawsuit against former directors of Insys Therapeutics, a public company which played a key role in the national opioid crisis.

Key Points: 
  • National trial firm Reid Collins & Tsai LLP represents Insys Liquidation Trust in lawsuit against former directors of Insys Therapeutics, a public company which played a key role in the national opioid crisis.
  • Settlement terms include $175 million judgment against the former directors, partial payment from their personal assets, and assignment of their claims to recover the balance from insurance companies.
  • AUSTIN, Texas, April 14, 2023 /PRNewswire/ -- Today, national trial firm Reid Collins & Tsai LLP ("Reid Collins") representing the Insys Liquidation Trust (the "Trust") announced a $175 million settlement agreement with certain former directors of Insys Therapeutics, Inc. ("Insys"), partially resolving civil litigation arising from its bankruptcy case.
  • Insys, a former public company, marketed and sold a highly addictive and inherently dangerous fentanyl spray to millions of people.

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results

Retrieved on: 
Giovedì, Luglio 15, 2021
Biotechnology, PTC Therapeutics, South Plainfield, New Jersey, PTC, Software, Companies

SOUTH PLAINFIELD, N.J., July 15, 2021 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29, 2021, at 4:30 p.m. (ET) after the closing of the market.

Key Points: 
  • SOUTH PLAINFIELD, N.J., July 15, 2021 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29, 2021, at 4:30 p.m. (ET) after the closing of the market.
  • The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 7064479.
  • A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at https://ir.ptcbio.com/events-presentations .
  • PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.

BrainStorm Appoints William K. White as Senior Vice President, Head of Market Access & Pricing

Retrieved on: 
Martedì, Settembre 29, 2020
Life sciences, Industries, Companies, Novartis, Insys Therapeutics, INSYS, Medication

NEW YORK, Sept. 29, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of William K. White as senior vice president, head of market access and pricing.Mr.

Key Points: 
  • NEW YORK, Sept. 29, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of William K. White as senior vice president, head of market access and pricing.Mr.
  • White has more than 25 years' experience in leading successful product commercialization and securing market access for innovative new medicines.
  • Mr. White was most recently Vice President of Patient and Market Access at Avexis, now Novartis Gene Therapies.
  • Mr. White has also held leadership positions in managed care and patient access at Insys Therapeutics and Lundbeck (formerly Ovation Pharmaceuticals).

Kessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities Litigation

Retrieved on: 
Lunedì, Agosto 17, 2020
Insys Therapeutics, Opioid epidemic, INSYS, Civil procedure, Lawsuit, Motion, Civil law, South African law, Economy of the United States, Law, Government, Civil procedure in South Africa

This notice provides only a summary of the information contained in the detailed Notice of (I)Proposed Settlement with Defendant Michael L. Babich; (II) Settlement Fairness Hearing; and (III) Motion for Litigation Expenses ("Settlement Notice").

Key Points: 
  • This notice provides only a summary of the information contained in the detailed Notice of (I)Proposed Settlement with Defendant Michael L. Babich; (II) Settlement Fairness Hearing; and (III) Motion for Litigation Expenses ("Settlement Notice").
  • You may obtain a copy of the Settlement Notice, along with the Claim Form, on the website for the Action, www.InsysRXSecuritiesLitigation.com .
  • You may also obtain a copy of the Settlement Notice and the Claim Form by writing to the Claims Administrator at Insys Therapeutics, Inc. Securities Litigation, c/o A.B.
  • Requests for the Settlement Notice and Claim Form should be made to the Claims Administrator:

Kessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities Litigation

Retrieved on: 
Lunedì, Luglio 20, 2020
Insys Therapeutics, Opioid epidemic, Civil law, Lawsuit, INSYS, Settlement, Economy of the United States, Companies, Class action

If approved, the Settlement will resolve all claims in the Action against Defendant Kapoor only.

Key Points: 
  • If approved, the Settlement will resolve all claims in the Action against Defendant Kapoor only.
  • Please Note: This settlement does not resolve any of the claims asserted against the other defendants in the Action.
  • You may also obtain a copy of the Settlement Notice and the Claim Form by writing to the Claims Administrator at Insys Therapeutics, Inc. Securities Litigation, c/o A.B.
  • Your Baker Settlement Claim Form will also beprocessed in connection with this Settlement.